DFTX
EquityDefinium Therapeutics, Inc.
Health Care · Biotechnology
$17.45
+17.45 (+0.00%)
Open
N/A
Day Range
$16.81 - $17.96
52W Range
$4.70 - $18.70
Volume
2M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Definium (DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Highlights: Strong Financial Position ...
Definium Therapeutics Q4 Earnings Call Highlights
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
Definium Therapeutics to Participate at Upcoming Investor Conferences
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
definiumtx.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for DFTX
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for DFTX.